Chronic hepatitis C virus infection is associated with all-cause and liver-related mortality in a cohort of HIV-infected patients with alcohol problems

Addiction

Volumn 109, Issue 1, 2014, Pages 62-70

  Fuster, Daniel ^a   Cheng, Debbie M ^a,b   Quinn, Emily K ^b   Nunes, David ^a   Saitz, Richard ^a,b   Samet, Jeffrey H ^a,b   Tsui, Judith I ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Alcohol; Hepatitis C; HIV; Mortality

Indexed keywords

ADULT; ALCOHOLISM; CAUSE OF DEATH; CHRONIC HEPATITIS C; COHORT ANALYSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; LIVER DISEASE; MALE; MIDDLE AGED; MIXED INFECTION; MORTALITY; PROPORTIONAL HAZARDS MODEL;

ADULT; ALCOHOL-RELATED DISORDERS; CAUSE OF DEATH; COHORT STUDIES; COINFECTION; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER DISEASES; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS;

EID: 84890150002     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.12367     Document Type: Article

References (55)

1. Bica I., McGovern B., Dhar R., Stone D., McGowan K., Scheib R. etal. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 492-497.
2. Weber R., Sabin C. A., Friis-Moller N., Reiss P., El-Sadr W. M., Kirk O. etal. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166: 1632-1641.
3. Justice A. C., Freiberg M. S., Tracy R., Kuller L., Tate J. P., Goetz M. B. etal. Does an Index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV? Clin Infect Dis 2012; 54: 984-994.
4. Kim A. Y., Chung R. T. Coinfection with HIV-1 and HCV-a one-two punch. Gastroenterology 2009; 137: 795-814.
5. Nelson K. E. The impact of chronic hepatitis C virus infection on mortality. J Infect Dis 2012; 206: 461-463.
6. Freiberg M. S., Cheng D. M., Kraemer K. L., Saitz R., Kuller L. H., Samet J. H. The association between hepatitis C infection and prevalent cardiovascular disease among HIV-infected individuals. AIDS 2007; 21: 193-197.
7. Bedimo R., Westfall A. O., Mugavero M., Drechsler H., Khanna N., Saag M. Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. HIV Med 2010; 11: 462-468.
8. Guiltinan A. M., Kaidarova Z., Custer B., Orland J., Strollo A., Cyrus S. etal. Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors. Am J Epidemiol 2008; 167: 743-750.
9. Tsui J. I., Whooley M. A., Monto A., Seal K., Tien P. C., Shlipak M. Association of hepatitis C virus seropositivity with inflammatory markers and heart failure in persons with coronary heart disease: data from the Heart and Soul study. J Card Fail 2009; 15: 451-456.
10. Grebely J., Dore G. J. What is killing people with hepatitis C virus infection? Semin Liver Dis 2011; 31: 331-339.
11. Campbell J. V., Hagan H., Latka M. H., Garfein R. S., Golub E. T., Coady M. H. etal. High prevalence of alcohol use among hepatitis C virus antibody positive injection drug users in three US cities. Drug Alcohol Depend 2006; 81: 259-265.
12. Samet J. H., Cheng D. M., Libman H., Nunes D. P., Alperen J. K., Saitz R. Alcohol consumption and HIV disease progression. J Acquir Immune Defic Syndr 2007; 46: 194-199.
13. Samet J. H., Phillips S. J., Horton N. J., Traphagen E. T., Freedberg K. A. Detecting alcohol problems in HIV-infected patients: use of the CAGE questionnaire. AIDS Res Hum Retroviruses 2004; 20: 151-155.
14. Folstein M. F., Folstein S. E., McHugh P. R. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
15. Smith K. L., Horton N. J., Saitz R., Samet J. H. The use of the Mini-Mental State Examination in recruitment for substance abuse research studies. Drug Alcohol Depend 2006; 82: 231-237.
16. Manos M. M., Leyden W. A., Murphy R. C., Terrault N. A., Bell B. P. Limitations of conventionally derived chronic liver disease mortality rates: results of a comprehensive assessment. Hepatology 2008; 47: 1150-1157.
17. Walley A. Y., Cheng D. M., Libman H., Nunes D., Horsburgh C. R., Jr, Saitz R. etal. Recent drug use, homelessness and increased short-term mortality in HIV-infected persons with alcohol problems. AIDS 2008; 22: 415-420.
18. Sobell L. C., Brown J., Leo G. I., Sobell M. B. The reliability of the Alcohol Timeline Followback when administered by telephone and by computer. Drug Alcohol Depend 1996; 42: 49-54.
19. Russell M., Marshall J. R., Trevisan M., Freudenheim J. L., Chan A. W., Markovic N. etal. Test-retest reliability of the cognitive lifetime drinking history. Am J Epidemiol 1997; 146: 975-981.
20. Kalbfleisch J. D., Prentice R. L., editors. The Statistical Analysis of Failure Time Data. Hoboken, NJ: J. Wiley; 2002.
21. Hernando V., Perez-Cachafeiro S., Lewden C., Gonzalez J., Segura F., Oteo J. A. etal. All-cause and liver-related mortality in HIV positive subjects compared to the general population: differences by HCV co-infection. J Hepatol 2012; 57: 743-751.
22. Berenguer J., Alejos B., Hernando V., Viciana P., Salavert M., Santos I. etal. Trends in mortality according to hepatitis C virus serostatus in the era of combination antiretroviral therapy. AIDS 2012; 26: 2241-2246.
23. Branch A. D., Van Natta M. L., Vachon M. L., Dieterich D. T., Meinert C. L., Jabs D. A. etal. Mortality in hepatitis C virus-infected patients with a diagnosis of AIDS in the era of combination antiretroviral therapy. Clin Infect Dis 2012; 55: 137-144.
24. Sanmartin R., de Felipe E., Tor J., Sanvicens A., Barluenga E., Martinez E. etal. Effect of liver fibrosis on long-term mortality in HIV/hepatitis C virus-coinfected individuals who are evaluated to receive interferon therapies in the highly active antiretroviral therapy era. AIDS Res Hum Retroviruses 2012; 28: 1235-1243.
25. Obel N., Omland L. H., Kronborg G., Larsen C. S., Pedersen C., Pedersen G. etal. Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART: a population-based nationwide cohort study. PLOS ONE 2011; 6: e22698.
26. Saitz R. Clinical practice. Unhealthy alcohol use. N Engl J Med 2005; 352: 596-607.
27. Siu L., Foont J., Wands J. R. Hepatitis C virus and alcohol. Semin Liver Dis 2009; 29: 188-199.
28. Salmon-Ceron D., Lewden C., Morlat P., Bevilacqua S., Jougla E., Bonnet F. etal. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 2005; 42: 799-805.
29. Omland L. H., Jepsen P., Weis N., Christensen P. B., Laursen A. L., Nielsen H. etal. Mortality in HIV-infected injection drug users with active vs cleared hepatitis C virus-infection: a population-based cohort study. J Viral Hepatol 2010; 17: 261-268.
30. Larsen M. V., Omland L. H., Gerstoft J., Larsen C. S., Jensen J., Obel N. etal. Impact of injecting drug use on mortality in Danish HIV-infected patients: a nation-wide population-based cohort study. Addiction 2010; 105: 529-535.
31. Nunes D., Saitz R., Libman H., Cheng D. M., Vidaver J., Samet J. H. Barriers to treatment of hepatitis C in HIV/HCV-coinfected adults with alcohol problems. Alcohol Clin Exp Res 2006; 30: 1520-1526.
32. Pineda J. A., Garcia-Garcia J. A., Aguilar-Guisado M., Rios-Villegas M. J., Ruiz-Morales J., Rivero A. etal. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology 2007; 46: 622-630.
33. Matser A., Urbanus A., Geskus R., Kretzschmar M., Xiridou M., Buster M. etal. The effect of hepatitis C treatment and human immunodeficiency virus (HIV) co-infection on the disease burden of hepatitis C among injecting drug users in Amsterdam. Addiction 2012; 107: 614-623.
34. Berenguer J., Alvarez-Pellicer J., Martin P. M., Lopez-Aldeguer J., Von-Wichmann M. A., Quereda C. etal. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009; 50: 407-413.
35. El-Kamary S. S., Jhaveri R., Shardell M. D. All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population. Clin Infect Dis 2011; 53: 150-157.
36. Lee M. H., Yang H. I., Lu S. N., Jen C. L., You S. L., Wang L. Y. etal. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012; 206: 469-477.
37. Butt A. A., Xiaoqiang W., Budoff M., Leaf D., Kuller L. H., Justice A. C. Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis 2009; 49: 225-232.
38. Lee M. H., Yang H. I., Wang C. H., Jen C. L., Yeh S. H., Liu C. J. etal. Hepatitis C virus infection and increased risk of cerebrovascular disease. Stroke 2010; 41: 2894-2900.
39. Tsui J. I., Vittinghoff E., Shlipak M. G., Bertenthal D., Inadomi J., Rodriguez R. A. etal. Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Arch Intern Med 2007; 167: 1271-1276.
40. Giordano T. P., Henderson L., Landgren O., Chiao E. Y., Kramer J. R., El-Serag H. etal. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA 2007; 297: 2010-2017.
41. Greub G., Ledergerber B., Battegay M., Grob P., Perrin L., Furrer H. etal. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356: 1800-1805.
42. Backus L. I., Phillips B. R., Boothroyd D. B., Mole L. A., Burgess J., Rigsby M. O. etal. Effects of hepatitis C virus coinfection on survival in veterans with HIV treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2005; 39: 613-619.
43. Chen T. Y., Ding E. L., Seage Iii G. R., Kim A. Y. Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis 2009; 49: 1605-1615.
44. Grebely J., Raffa J. D., Lai C., Kerr T., Fischer B., Krajden M. etal. Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents. J Viral Hepatol 2011; 18: 32-41.
45. Berenguer J., Rodriguez E., Miralles P., Von Wichmann M. A., Lopez-Aldeguer J., Mallolas J. etal. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 2012; 57: 728-736.
46. Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study Group, Smith C., Sabin C. A., Lundgren J. D., Thiebaut R., Weber R. etal. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010; 24: 1537-1548.
47. Neuman M. G., Sha K., Esguerra R., Zakhari S., Winkler R. E., Hilzenrat N. etal. Inflammation and repair in viral hepatitis C. Dig Dis Sci 2008; 53: 1468-1487.
48. Freiberg M. S., Chang C. C., Skanderson M., McGinnis K., Kuller L. H., Kraemer K. L. etal. The risk of incident coronary heart disease among veterans with and without HIV and hepatitis C. Circ Cardiovasc Qual Outcomes 2011; 4: 425-432.
49. Mocroft A., Neuhaus J., Peters L., Ryom L., Bickel M., Grint D. etal. Hepatitis B and C co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adults. PLOS ONE 2012; 7: e40245.
50. Wyatt C. M., Malvestutto C., Coca S. G., Klotman P. E., Parikh C. R. The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis. AIDS 2008; 22: 1799-1807.
51. Amin J., Law M. G., Bartlett M., Kaldor J. M., Dore G. J. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet 2006; 368: 938-945.
52. Innes H. A., Hutchinson S. J., Allen S., Bhattacharyya D., Bramley P., Delahooke T. E. etal. Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care. Hepatology 2011; 54: 1547-1558.
53. Wu C., Chang H. G., McNutt L. A., Smith P. F. Estimating the mortality rate of hepatitis C using multiple data sources. Epidemiol Infect 2005; 133: 121-125.
54. Omland L. H., Krarup H., Jepsen P., Georgsen J., Harritshoj L. H., Riisom K. etal. Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study. J Hepatol 2010; 53: 36-42.
55. Kielland K. B., Skaug K., Amundsen E. J., Dalgard O. All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: a controlled study. J Hepatol 2013; 58: 31-37.